jRCTs031200038招募中不适用
Diagnostic laparoscopy with 5-aminolevulinic acid for peritoneal metastasis from colorectal cancer
未提供0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 主要终点
- Comparison of sensitivity between white light and blue light
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Diagnostic Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 75age old under（—）
- 性别
- All
入选标准
- •Patient diagnosed or suspiciously as peritoneal metastasis from colorectal cancer
- •Patient aged from 20 to 75 years
- •Patient with ECOG performance status of 0 or 1
排除标准
- •Porphyria. Patients with a history of sun or photosensitivity.
- •Patients with a history of hypersensitivity to porphyrins.
- •Patients taking drugs that may induce photosensitivity.
- •In addition, patients whose physician judged that participation in this study was inappropriate.
结局指标
主要结局
Comparison of sensitivity between white light and blue light
ALA-PDD increases the accuracy of peritoneal metastasis
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOADCTIS2023-508363-79-00Alnylam Pharmaceuticals Inc.59
已完成
不适用
ACL-PETjRCT1041220111Toshifumi Gabata10
进行中（未招募）
1 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.CTIS2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
进行中（未招募）
1 期
Bioequivalence of Amoxicillin and Clavulanic Acid 500 mg/125 mg Film-Coated Tablets in Healthy Participants Under Fed Conditions.o medical condition.CTIS2024-513751-32-00Bial Portela & Ca S.A.48
进行中（未招募）
不适用
Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada®) + Lopinavir/ritonavir (kaletra®) versus TDF-FTC (Truvada®) + raltegravir (Isentress®)HIV- post exposition prophylaxisEUCTR2011-003799-35-ESFundació Clínic per a la Recerca Biomèdica189